Your Messages Inbox
Your Article Summary
See Latest ArticlesRichter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease
b3c newswire, 03/04/09
Richter-Helm BioLogics GmbH and Co. KG and Athera Biotechnologies AB have signed an agreement for the development and manufacturing of Athera's novel product for prevention of plaque rupture and athero-thrombosis through binding of the protein, Annexin A5, to endothelium. The recombinant protein Annexin A5 is intended for the treatment of patients with Acute Coronary Syndrome and who are at imminent risk for Myocardial Infarction.
Today in Biotechnology...keeping you current
Receive free subspecialty "5-minute updates" via email
Development of biomaterial scaffold for nerve tissue engineering: Biomaterial mediated neural regeneration
BMC: Journal of Biomedical Science, 11/30/09
ImmunoGen, Inc. Announces Clinical Data Presentations on Three TAP Compounds at Upcoming ASH Annual Meeting and Exposition
ImmunoGen, Inc., 11/25/09
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09
Harris Corp. Buys VA Contractor
HealthDataManagement, 11/23/09
Article Search
Sponsor